Abstract 43P
Background
Breast cancer remains a significant concern worldwide. Risk-based screening, which tailors screening recommendations to individual risk levels, has been shown to enhance patient stratification. However, most research on model development focuses on Western populations, leaving the predictive accuracy of these models for Southeast Asian populations largely uncharacterized.
Methods
We conducted an observational case-control study comprising 305 Indonesian women to assess the applicability of published risk models to the local population. We employed a combined risk model to classify patients as either elevated or average risk. Our combined model evaluates two separate risk factors: genetic risk, assessed using ancestry-adjusted PRS scores based on the Mavaddat model, and clinical risk, evaluated using the Gail model. The performance of each individual model and their combined effectiveness were analyzed using the Area Under the Curve (AUC) and Odds Ratio (OR).
Results
Individual risk models retained their predictive efficacy in the Indonesian context. Specifically, the AUC achieved for genetic risk is AUC of 0.674 (p = 1.28 x 10-3; Risk group: OR = 3.16; p = 2.5 x 10-1). For clinical risk, the AUC stands at 0.674 (p = 5.16 x 10-4; Risk group: OR = 7.636; p = 6.1 x 10-3). Remarkably, when combined, the AUC increased to 0.701 (Risk group: OR= 3.897; p = 4.28 x 10-2), signifying the benefits of a multi-factor model. Based on a subset of the samples taken from this study, the Nala Breast Cancer Risk genetic risk algorithm generated higher AUC when compared to a leading third-party software that uses the same PRS model for breast cancer (0.63 vs 0.55). This improvement is primarily due to our method of translating PRS scores into categorical outcomes, which integrates localized disease incidence and mortality rates.
Conclusions
Our findings demonstrate for the first time the applicability of the Polygenic Risk Score using Mavaddat model and clinical score using Gail model to Indonesian populations. In addition, our study shows that, within this demographic, combined risk models provide a superior predictive framework compared to single-factor approaches.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
NalaGenetics.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract